1132679-65-2Relevant academic research and scientific papers
Catalytic Aerobic Cross-Dehydrogenative Coupling of Azlactones en Route to α,α-Disubstituted α-Amino Acids
Tsuji, Taro,Tanaka, Takafumi,Tanaka, Tsukushi,Yazaki, Ryo,Ohshima, Takashi
, p. 4164 - 4170 (2020/06/04)
We developed a catalytic aerobic method to synthesize α,α-disubstituted α-amino acids through cross-dehydrogenative coupling of azlactones. Combining an iron catalyst with a bisoxazolidine ligand resulted in high catalytic performance, and cross-coupling with an indole proceeded smoothly under aerobic conditions. A wide variety of α-aryl and aliphatic amino acid derived azlactones were applied to the present catalysis. In addition, a quaternary carbon could be constructed using oxindole and benzofuranone under aerobic conditions.
Enantioselective iridium catalyzed α-alkylation of azlactones by a tandem asymmetric allylic alkylation/aza-Cope rearrangement
Bai, Xue-Dan,Zhang, Qing-Feng,He, Ying
, p. 5547 - 5550 (2019/05/21)
The development of an iridium catalyzed enantioselective α-alkylation of azlactones has been described. The reaction provides rapid access to a wide range of enantio-enriched quaternary carbon center allylated 2,4-diaryloxazol-5(2H)-ones in excellent yiel
Inhibition of the human proteasome by imidazoline scaffolds
Azevedo, Lauren M.,Lansdell, Theresa A.,Ludwig, Jacob R.,Mosey, Robert A.,Woloch, Daljinder K.,Cogan, Dillon P.,Patten, Gregory P.,Kuszpit, Michael R.,Fisk, Jason S.,Tepe, Jetze J.
, p. 5974 - 5978 (2013/08/23)
The proteasome has emerged as the primary target for the treatment of multiple myeloma. Unfortunately, nearly all patients develop resistance to competitive-type proteasome inhibitors such as bortezomib. Herein, we describe the optimization of noncompetit
